NHS England consultation on draft policy for the delivery of stereotactic ablative radiotherapy (SABR) for the treatment of localised prostate cancer (adults)

Posted 7th Mar 2025

Stereotactic ablative radiotherapy (SABR) is recommended to be available as a routine commissioning treatment option for adults with low and intermediate risk localised prostate cancer who do not require androgen deprivation therapy (ADT) as an alternative to moderately hypofractionated external beam radiotherapy (EBRT) within the criteria set out in this document.

The policy proposition is restricted to adults (≥18 years old) as there is insufficient evidence to confirm safety in those age groups not included in the policy proposition. As a key stakeholder, we would like to hear your views on this new commissioning policy proposition before NHS England further considers it. 

Stakeholders are invited to respond to the consultation by 20th March 2025.

Please read the policy proposition 

• 2106 Stereotactic ablative radiotherapy (SABR)- policy proposition.pdf

You may also wish to read and comment on these supporting documents

• 2106 Stereotactic ablative radiotherapy (SABR) for the treatment of localised prostate cancer EHIA.pdf
• 2106 Stereotactic ablative radiotherapy (SABR) for the treatment of localised prostate cancer PIA.pdf
• 2106 Stereotactic ablative radiotherapy (SABR)- Evidence Review.pdf

This document replaces Clinical Commissioning Policy

• The use of stereotactic ablative radiotherapy in the treatment of prostate cancer.pdf 

This document should be read in conjunction with Clinical Commissioning Policy

• Hypofractionated external beam radiotherapy in the treatment of prostate cancer.pdf 

This stakeholder testing is open for 14 days, please submit your feedback by using this form https://forms.office.com/e/j6AQyFmyt1 by 20 March 2025.